Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business June 14, 2024 SALT LAKE CITY, May 07, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the... Continue Reading
Myriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9 Countries June 12, 2024 New sponsored testing program leverages Myriad’s MyChoice Tests for patients with high-grade serous ovarian cancer SALT LAKE CITY, June 11, 2024 (GLOBE NE... Continue Reading
New publication: Real-world study prospectively shows prognostic and predictive accuracy May 22, 2024 We are excited to share the latest prospective findings from a study entitled “Long-term prospective outcome data using EndoPredict as risk stratification an... Continue Reading
NICE in UK recommends EndoPredict® for tailored treatment of lymph node positive early breast cancer May 13, 2024 New guidance from the National Institute for Health and Care Excellence (NICE)1 The National Institute for Health and Care Excellence (NICE) in the UK has i... Continue Reading
Phase III validation of EndoPredict confirms prognostic power May 6, 2024 Prognostic value of EndoPredict test in patients with hormone receptor positive, human epidermal growth factor receptor 2-negative primary breast cancer screen... Continue Reading
MyChoice CDx test implementation insights: From study to practice April 30, 2024 Successful Implementation of MyChoiceCDx Test in Nordic countries leading the way in establishing a collaboration with Myriad to conduct local testing ... Continue Reading
Optimizing HRD testing in ovarian cancer: Recommendations to achieve up to 98% conclusive test results March 15, 2024 Recent research led by Prof. Dr. med. Carsten Denkert and Marcel Romey reveals interesting data on systematic analysis of HRD testing in ovarian cancer patient... Continue Reading
The ESMO-ESGO-ESP consensus is advocating for the use of genomic instability tests validated in phase III trials March 5, 2024 MyChoice is the only HRD test with Level of Evidence 1A, prospectively validated in Phase III studies At the forefront of ovarian cancer diagnostics, MyChoi... Continue Reading
Updated ESMO Guidelines 2024 February 26, 2024 Level of Evidence (LoE) 1A for all gene expression assays in early ER+ HER2- breast cancer We are pleased to share the latest insights from the ESMO Clinica... Continue Reading
MyChoice CDx® Plus HRD test validated for local pathology labs in real-world study March 1, 2023 Real-world validation study with over 500 tumor samples shows MyChoice CDx Plus can be performed in a decentralized setting1 1st December 2022 Myriad Geneti... Continue Reading